Marc L Citron

Summary

Publications

  1. ncbi Dose density in adjuvant chemotherapy for breast cancer
    Marc L Citron
    Albert Einstein College of Medicine, Bronx, New York, USA
    Cancer Invest 22:555-68. 2004
  2. ncbi Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia
    Marc L Citron
    ProHEALTH Care Associates, LLP, 2800 Marcus Ave, Lake Success, NY 11042, USA
    J Clin Oncol 21:1431-9. 2003
  3. ncbi Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
    Donald A Berry
    University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    JAMA 295:1658-67. 2006
  4. ncbi Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience
    Hyman B Muss
    University of Vermont, Vermont Cancer Center, Burlington, VT 05405, USA
    J Clin Oncol 25:3699-704. 2007
  5. ncbi Adipose concentrations of organochlorine compounds and breast cancer recurrence in Long Island, New York
    Joshua E Muscat
    Institute for Cancer Prevention, Valhalla, New York 10595, USA
    Cancer Epidemiol Biomarkers Prev 12:1474-8. 2003
  6. ncbi Dose-dense chemotherapy for node-positive breast cancer
    Marc L Citron
    Ann Intern Med 142:227. 2005

Detail Information

Publications6

  1. ncbi Dose density in adjuvant chemotherapy for breast cancer
    Marc L Citron
    Albert Einstein College of Medicine, Bronx, New York, USA
    Cancer Invest 22:555-68. 2004
    ..This article discusses the rationale for dose-dense therapy and reviews the results with dose-dense adjuvant regimens in recent clinical trials in breast cancer...
  2. ncbi Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia
    Marc L Citron
    ProHEALTH Care Associates, LLP, 2800 Marcus Ave, Lake Success, NY 11042, USA
    J Clin Oncol 21:1431-9. 2003
    ....
  3. ncbi Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
    Donald A Berry
    University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    JAMA 295:1658-67. 2006
    ..Breast cancer estrogen-receptor (ER) status is useful in predicting benefit from endocrine therapy. It may also help predict which patients benefit from advances in adjuvant chemotherapy...
  4. ncbi Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience
    Hyman B Muss
    University of Vermont, Vermont Cancer Center, Burlington, VT 05405, USA
    J Clin Oncol 25:3699-704. 2007
    ..We compared toxicity of older and younger patients in three randomized trials of adjuvant chemotherapy...
  5. ncbi Adipose concentrations of organochlorine compounds and breast cancer recurrence in Long Island, New York
    Joshua E Muscat
    Institute for Cancer Prevention, Valhalla, New York 10595, USA
    Cancer Epidemiol Biomarkers Prev 12:1474-8. 2003
    ..9-5.1). In contrast to previous data showing no relationship between OC exposure and risk of breast cancer in these women, adipose PCB concentrations were associated with tumor recurrence. Pesticide levels were not related to recurrence...
  6. ncbi Dose-dense chemotherapy for node-positive breast cancer
    Marc L Citron
    Ann Intern Med 142:227. 2005